Evidence Hub

A Case Report: Ertapenem-Induced Encephalopathy

Lim RB, Huang B, Meng AZ

Cureus, 2025

Abstract

We present a 46-year-old patient who developed acute psychotic and neurological symptoms associated with the use of intravenous ertapenem, a carbapenem antibiotic. He was hospitalized following a road traffic accident where he sustained an open fracture over the right lower limb requiring intravenous antibiotics. He started to exhibit hallucinations, odd beliefs and twitching movements two weeks after the initiation of ertapenem. Other organic causes for this acute change in behaviour were ruled out. His symptoms continued despite the use of antipsychotics but quickly resolved within three days of the withdrawal of ertapenem. Antibiotic-induced encephalopathy, which can manifest as neurological or psychiatric symptoms, is uncommon but clinically significant. Among these, carbapenems have been occasionally associated with encephalopathy through GABAergic inhibition. This case highlights the importance of recognizing ertapenem-induced neuropsychiatric complications even in patients without conventional risk factors, underscoring the need for vigilance when evaluating acute behavioural changes during antibiotic therapy.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free